|  Nederlands |  English |
 
 
<News room / Press Releases>
30/01/2006: Janssen Pharmaceutica Finalist in Facility of the Year Competition - 2006

Jan. 30, 2006 – The Small Volume Area installation of Janssen Pharmaceutica, Geel placed among the five finalists for the Facility of the Year award, organized by ISPE, INTERPHEX and Pharmaceutical Processing. This annual worldwide competition for pharmaceutical companies honors projects that make use of innovative technologies. The winner of this prestigious accolade will be announced on March 23.
 
   
 
 
 

Janssen Pharmaceutica, Geel plays a crucial role within Johnson & Johnson in the production of medically active substances. About two-thirds of the worldwide chemical production in the pharmaceutical sector is carried out by the Chemical Production group in Geel. Johnson & Johnson is the fourth largest pharmaceutical company in the world.

In the Small Volume Area (SVA) installation the highly active powders are ground and sieved to the desired granule size (in some cases down to 0.002 mm). That is done in a completely closed-off installation. The combination of the state-of-the-art grinding installation and the hi-tech separation by means of glove compartments (otherwise known as isolators) adds up to uniqueness on a world scale.

Together with three other production installations, the SVA forms part of the High Containment Production Chain. This chain of four separate hi-tech installations was inaugurated on June 20, 2005 in the presence of Marc Verwilghen, Minister for Economy, Energy, Foreign Trade and Science Policy. Owing to the so-called containment technology that they use, each of these installations is totally sealed off, which confers substantial advantages as far as quality and safety are concerned.

For more information about the Facility of the Year award, visit wwwsg.

General Company Information
Within the Johnson & Johnson group, Janssen Pharmaceutica is a worldwide Center of Excellence for integrated R&D, production and general services. In Belgium, the company has sites in Beerse, Geel and Olen, which together account for a workforce of 4,350 persons. With more than 80 drugs to its credit, the company is one of the most innovative in the world and its products are used worldwide in human and animal medicine, and plant and material protection.

In the Chemical Production department of Janssen Pharmaceutica, Geel, medically active substances are produced on a large scale. The department was set up more than 30 years ago and has about 800 staff members.
 
Press Releases
13/11/2006 Janssen Pharmaceutica Builds New Plant
17/10/2006 Xian-Janssen Pharmaceutical en het Qinshihuang Terracotta Army Museum in Xian ondertekenen een NIEUWE overeenkomst
12/10/2006 Gender Diversity: Not Just a Women’s Matter I ndustry, Government and Universities Learn from Each Other How to Address This Question in Practice
12/09/2006 RNAi Pioneer Craig Mello Named Inaugural Winner
09/09/2006 Janssen Pharmaceutica Gives “Partnership Award” to Eight Suppliers of Chemical Production
04/07/2006 Annual Report 2005
29/06/2006 Belgian Economic Mission in Russia
26/06/2006 PREZISTA™ approved by FDA in the US!
An unusual achievement that everyone can be proud of.
24/05/2006 Innovation and collaboration the driving force behind the startup of production of Tibotec HIV/AIDS drugs at Janssen Pharmaceutica Geel
19/04/2006 Her Excellency Minister Kathleen Van Brempt presents Certificate of Appreciation to 25 sheltered workshop employees working at Janssen Pharmaceutica
24/02/2006 Janssen Pharmaceutica Wins Most Attractive Belgian Employer Award for the Second Time in Six Years
30/01/2006 Janssen Pharmaceutica finalist Facility of the Year 2006
19/01/2006 Johnson & Johnson senior management meets with Prime Minister Verhofstadt and Deputy Prime Minister Reynders: 100 Million euros to be invested in Belgium in 2006
05/01/2006 Xian-Janssen Selected as Employer of the Year in China
 
<< Back
 

 
 
© Janssen Pharmaceutica N.V., 1997-2010.

This site is published by Janssen Pharmaceutica NV and is intended for visitors from Europe. Use of the site constitutes your consent to application of European laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice.